These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 22464410

  • 1. The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome.
    Vieira CS, Martins WP, Fernandes JB, Soares GM, dos Reis RM, de Sá MF, Ferriani RA.
    Contraception; 2012 Sep; 86(3):268-75. PubMed ID: 22464410
    [Abstract] [Full Text] [Related]

  • 2. Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.
    Gode F, Karagoz C, Posaci C, Saatli B, Uysal D, Secil M, Akdeniz B.
    Arch Gynecol Obstet; 2011 Oct; 284(4):923-9. PubMed ID: 21140159
    [Abstract] [Full Text] [Related]

  • 3. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact.
    Guido M, Romualdi D, Campagna G, Ricciardi L, Bompiani A, Lanzone A.
    Reprod Sci; 2010 Aug; 17(8):767-75. PubMed ID: 20595709
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up.
    Yildizhan R, Gokce AI, Yildizhan B, Cim N.
    Gynecol Endocrinol; 2015 May; 31(5):396-400. PubMed ID: 25739031
    [Abstract] [Full Text] [Related]

  • 5. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
    Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ.
    Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
    [Abstract] [Full Text] [Related]

  • 6. Clinical, hormonal and metabolic parameters in women with PCOS with different combined oral contraceptives (containing chlormadinone acetate versus drospirenone).
    Podfigurna A, Meczekalski B, Petraglia F, Luisi S.
    J Endocrinol Invest; 2020 Apr; 43(4):483-492. PubMed ID: 31654312
    [Abstract] [Full Text] [Related]

  • 7. Oral contraceptive containing chlormadinone acetate and ethinylestradiol reduces plasma concentrations of matrix metalloproteinase-2 in women with polycystic ovary syndrome.
    Gomes VA, Vieira CS, Jacob-Ferreira AL, Belo VA, Soares GM, França JB, Ferriani RA, Tanus-Santos JE.
    Basic Clin Pharmacol Toxicol; 2012 Sep; 111(3):211-6. PubMed ID: 22510229
    [Abstract] [Full Text] [Related]

  • 8. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM.
    Contraception; 2010 Aug; 82(2):131-8. PubMed ID: 20654753
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
    Harmanci A, Cinar N, Bayraktar M, Yildiz BO.
    Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Metformin improves endothelial function and carotid intima media thickness in patients with PCOS.
    Kaya MG, Yildirim S, Calapkorur B, Akpek M, Unluhizarci K, Kelestimur F.
    Gynecol Endocrinol; 2015 May; 31(5):401-5. PubMed ID: 25791462
    [Abstract] [Full Text] [Related]

  • 15. 17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
    Maier PS, Mattiello SS, Lages L, Spritzer PM.
    Gynecol Endocrinol; 2012 Aug; 28(8):606-10. PubMed ID: 22329763
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V, Di Sabatino A, Musacchio MC, Morgante G, Scolaro V, Cianci A, Petraglia F.
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [Abstract] [Full Text] [Related]

  • 18. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, Diamanti-Kandarakis E.
    Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
    [Abstract] [Full Text] [Related]

  • 19. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
    Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO.
    Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.